 Corey Lyon
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 192 | 1.150 |
Why?
| | Anticoagulants | 2 | 2025 | 724 | 1.000 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 270 | 0.880 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2024 | 2524 | 0.880 |
Why?
| | Hypertension | 4 | 2022 | 1250 | 0.870 |
Why?
| | Glucocorticoids | 3 | 2018 | 534 | 0.820 |
Why?
| | Venous Thrombosis | 1 | 2025 | 192 | 0.800 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 68 | 0.790 |
Why?
| | Medical Staff | 2 | 2022 | 17 | 0.790 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 268 | 0.780 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2024 | 105 | 0.740 |
Why?
| | Metformin | 2 | 2023 | 330 | 0.720 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 1038 | 0.720 |
Why?
| | Papillomavirus Infections | 2 | 2020 | 364 | 0.710 |
Why?
| | Sphygmomanometers | 1 | 2021 | 6 | 0.700 |
Why?
| | Insulin, Isophane | 1 | 2021 | 21 | 0.690 |
Why?
| | Automation | 1 | 2021 | 101 | 0.680 |
Why?
| | Humans | 56 | 2025 | 141010 | 0.670 |
Why?
| | Insulin Glargine | 1 | 2021 | 84 | 0.660 |
Why?
| | Prediabetic State | 1 | 2023 | 251 | 0.650 |
Why?
| | Employment | 1 | 2022 | 180 | 0.650 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 144 | 0.650 |
Why?
| | Preventive Health Services | 1 | 2022 | 154 | 0.640 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 32 | 0.630 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 431 | 0.630 |
Why?
| | Aspirin | 2 | 2020 | 384 | 0.630 |
Why?
| | Smoking Cessation | 1 | 2024 | 431 | 0.630 |
Why?
| | Ganglion Cysts | 1 | 2020 | 10 | 0.630 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 40 | 0.630 |
Why?
| | Post-Concussion Syndrome | 1 | 2023 | 182 | 0.620 |
Why?
| | Papillomaviridae | 1 | 2020 | 121 | 0.620 |
Why?
| | C-Reactive Protein | 2 | 2021 | 416 | 0.610 |
Why?
| | Wrist | 1 | 2020 | 58 | 0.600 |
Why?
| | Anti-Bacterial Agents | 2 | 2021 | 1864 | 0.600 |
Why?
| | Spironolactone | 1 | 2019 | 33 | 0.600 |
Why?
| | Diuretics | 1 | 2019 | 72 | 0.590 |
Why?
| | Probiotics | 1 | 2019 | 57 | 0.590 |
Why?
| | Ketorolac | 1 | 2019 | 25 | 0.580 |
Why?
| | Memory | 1 | 2021 | 263 | 0.580 |
Why?
| | Glucosamine | 1 | 2018 | 14 | 0.580 |
Why?
| | Erythromycin | 1 | 2018 | 20 | 0.570 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 346 | 0.570 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 14 | 0.560 |
Why?
| | Glycemic Index | 1 | 2018 | 26 | 0.550 |
Why?
| | Viscosupplements | 1 | 2018 | 11 | 0.550 |
Why?
| | Ureteral Calculi | 1 | 2018 | 15 | 0.550 |
Why?
| | Sweating | 1 | 2018 | 41 | 0.550 |
Why?
| | Acute Pain | 1 | 2019 | 54 | 0.550 |
Why?
| | Musculoskeletal System | 1 | 2018 | 49 | 0.540 |
Why?
| | Hot Flashes | 1 | 2018 | 87 | 0.520 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 122 | 0.520 |
Why?
| | Testosterone | 1 | 2021 | 404 | 0.520 |
Why?
| | Patient Education as Topic | 2 | 2022 | 769 | 0.510 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 40 | 0.510 |
Why?
| | Family Practice | 2 | 2018 | 440 | 0.500 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 190 | 0.500 |
Why?
| | Labor, Obstetric | 1 | 2017 | 66 | 0.500 |
Why?
| | Warfarin | 1 | 2017 | 168 | 0.490 |
Why?
| | Hypoglycemia | 1 | 2021 | 467 | 0.490 |
Why?
| | Athletic Injuries | 1 | 2023 | 525 | 0.490 |
Why?
| | Telemedicine | 2 | 2022 | 889 | 0.480 |
Why?
| | Melatonin | 1 | 2017 | 163 | 0.480 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 106 | 0.480 |
Why?
| | Methylprednisolone | 1 | 2016 | 64 | 0.470 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 181 | 0.470 |
Why?
| | Analgesics | 1 | 2018 | 231 | 0.470 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 30 | 0.470 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1545 | 0.470 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 227 | 0.470 |
Why?
| | Job Satisfaction | 1 | 2018 | 223 | 0.470 |
Why?
| | Migraine Disorders | 1 | 2017 | 106 | 0.470 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 283 | 0.470 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1604 | 0.460 |
Why?
| | Brain Concussion | 1 | 2023 | 588 | 0.450 |
Why?
| | Menopause | 1 | 2018 | 317 | 0.440 |
Why?
| | Drug Administration Schedule | 3 | 2025 | 771 | 0.420 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 809 | 0.420 |
Why?
| | Cough | 1 | 2015 | 133 | 0.410 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 501 | 0.400 |
Why?
| | Patient Care Team | 2 | 2018 | 664 | 0.400 |
Why?
| | Exercise Therapy | 1 | 2018 | 451 | 0.400 |
Why?
| | Antioxidants | 1 | 2017 | 593 | 0.400 |
Why?
| | Respiratory Tract Diseases | 1 | 2015 | 180 | 0.400 |
Why?
| | Myofascial Pain Syndromes | 2 | 2023 | 12 | 0.390 |
Why?
| | Acupuncture Therapy | 2 | 2023 | 23 | 0.390 |
Why?
| | Insulin | 1 | 2024 | 2458 | 0.390 |
Why?
| | Mass Screening | 2 | 2022 | 1305 | 0.390 |
Why?
| | Virus Diseases | 1 | 2015 | 215 | 0.380 |
Why?
| | Behavior Therapy | 3 | 2023 | 282 | 0.360 |
Why?
| | Low Back Pain | 2 | 2023 | 109 | 0.350 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 501 | 0.350 |
Why?
| | Health Promotion | 1 | 2018 | 749 | 0.350 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 2091 | 0.340 |
Why?
| | Pain Measurement | 4 | 2023 | 555 | 0.320 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7939 | 0.310 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 142 | 0.280 |
Why?
| | Aged | 10 | 2021 | 24771 | 0.270 |
Why?
| | Organizational Innovation | 2 | 2019 | 128 | 0.270 |
Why?
| | Depression | 1 | 2017 | 1489 | 0.270 |
Why?
| | Female | 16 | 2023 | 75619 | 0.260 |
Why?
| | Abdomen, Acute | 1 | 2006 | 22 | 0.260 |
Why?
| | Azithromycin | 2 | 2018 | 98 | 0.250 |
Why?
| | Pregnancy | 4 | 2022 | 7034 | 0.250 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 317 | 0.250 |
Why?
| | Enuresis | 1 | 2005 | 3 | 0.240 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 13 | 0.240 |
Why?
| | Renal Agents | 1 | 2005 | 5 | 0.240 |
Why?
| | Middle Aged | 11 | 2021 | 34553 | 0.240 |
Why?
| | Treatment Outcome | 7 | 2021 | 11195 | 0.230 |
Why?
| | Hormone Replacement Therapy | 2 | 2023 | 102 | 0.200 |
Why?
| | Adult | 9 | 2022 | 39198 | 0.200 |
Why?
| | Fibromyalgia | 1 | 2023 | 53 | 0.200 |
Why?
| | Vaping | 1 | 2024 | 63 | 0.190 |
Why?
| | Age Factors | 2 | 2022 | 3291 | 0.190 |
Why?
| | Electronics | 1 | 2023 | 74 | 0.190 |
Why?
| | Naltrexone | 1 | 2023 | 101 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2047 | 0.190 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 715 | 0.180 |
Why?
| | Occult Blood | 1 | 2022 | 37 | 0.180 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1366 | 0.170 |
Why?
| | Postmenopause | 1 | 2023 | 369 | 0.170 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.170 |
Why?
| | Life Style | 1 | 2023 | 479 | 0.170 |
Why?
| | Fish Oils | 1 | 2020 | 26 | 0.170 |
Why?
| | United States | 5 | 2022 | 15252 | 0.170 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 39 | 0.170 |
Why?
| | Labor Stage, Second | 1 | 2020 | 3 | 0.160 |
Why?
| | Time Factors | 2 | 2023 | 6939 | 0.160 |
Why?
| | Prenatal Care | 1 | 2022 | 301 | 0.160 |
Why?
| | Inpatients | 1 | 2024 | 511 | 0.150 |
Why?
| | Colonoscopy | 1 | 2022 | 250 | 0.150 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 162 | 0.150 |
Why?
| | Ticlopidine | 1 | 2019 | 53 | 0.150 |
Why?
| | Systems Integration | 1 | 2018 | 38 | 0.150 |
Why?
| | Pain Management | 2 | 2023 | 397 | 0.140 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 6 | 0.140 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 35 | 0.140 |
Why?
| | Primary Prevention | 1 | 2020 | 202 | 0.140 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 13 | 0.140 |
Why?
| | Netherlands | 1 | 2018 | 86 | 0.140 |
Why?
| | Primary Health Care | 2 | 2019 | 1757 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2019 | 74 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Arthralgia | 1 | 2018 | 57 | 0.140 |
Why?
| | Visual Analog Scale | 1 | 2018 | 35 | 0.140 |
Why?
| | Citalopram | 1 | 2018 | 34 | 0.140 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 116 | 0.140 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 58 | 0.140 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 48 | 0.140 |
Why?
| | Yoga | 1 | 2018 | 30 | 0.140 |
Why?
| | Male | 9 | 2021 | 69945 | 0.140 |
Why?
| | Patients | 1 | 2019 | 179 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 416 | 0.130 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.130 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 142 | 0.130 |
Why?
| | Pain | 2 | 2023 | 779 | 0.130 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 176 | 0.130 |
Why?
| | Regression Analysis | 1 | 2019 | 1013 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 65 | 0.130 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 50 | 0.130 |
Why?
| | Blood Glucose | 2 | 2024 | 2274 | 0.130 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 48 | 0.120 |
Why?
| | Smoking | 1 | 2024 | 1572 | 0.120 |
Why?
| | Recurrence | 1 | 2020 | 1108 | 0.120 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 244 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2020 | 567 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 449 | 0.120 |
Why?
| | Exanthema | 1 | 2016 | 82 | 0.120 |
Why?
| | Psychiatry | 1 | 2018 | 185 | 0.120 |
Why?
| | Prednisone | 1 | 2016 | 228 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 824 | 0.110 |
Why?
| | Injections | 1 | 2016 | 191 | 0.110 |
Why?
| | Sleep | 1 | 2022 | 880 | 0.110 |
Why?
| | Diabetic Foot | 1 | 2015 | 24 | 0.110 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 477 | 0.110 |
Why?
| | Achilles Tendon | 1 | 2015 | 32 | 0.110 |
Why?
| | Acute Disease | 1 | 2018 | 1005 | 0.110 |
Why?
| | Hemorrhage | 1 | 2020 | 787 | 0.110 |
Why?
| | Burnout, Professional | 2 | 2019 | 453 | 0.110 |
Why?
| | Adolescent | 2 | 2025 | 22066 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 822 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2019 | 645 | 0.110 |
Why?
| | Tendon Injuries | 1 | 2015 | 67 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1655 | 0.100 |
Why?
| | Hospitalization | 1 | 2024 | 2259 | 0.100 |
Why?
| | Treatment Failure | 1 | 2015 | 354 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1042 | 0.100 |
Why?
| | Sulfonamides | 1 | 2018 | 568 | 0.100 |
Why?
| | Double-Blind Method | 1 | 2018 | 1979 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2015 | 594 | 0.100 |
Why?
| | Gestational Age | 1 | 2017 | 952 | 0.100 |
Why?
| | Young Adult | 2 | 2023 | 13675 | 0.100 |
Why?
| | Psychometrics | 1 | 2017 | 735 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 851 | 0.100 |
Why?
| | Osteomyelitis | 1 | 2015 | 143 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 337 | 0.100 |
Why?
| | Alphapapillomavirus | 1 | 2010 | 38 | 0.080 |
Why?
| | Child | 3 | 2025 | 22337 | 0.080 |
Why?
| | Colorado | 2 | 2019 | 4595 | 0.080 |
Why?
| | Child, Preschool | 1 | 2025 | 11474 | 0.080 |
Why?
| | Mental Disorders | 1 | 2018 | 1125 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2206 | 0.060 |
Why?
| | Prospective Studies | 1 | 2018 | 7797 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5932 | 0.050 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 325 | 0.050 |
Why?
| | Amitriptyline | 1 | 2023 | 24 | 0.050 |
Why?
| | Trigger Points | 1 | 2023 | 13 | 0.050 |
Why?
| | Blood Pressure | 2 | 2022 | 1740 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3731 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1490 | 0.050 |
Why?
| | Dermoscopy | 1 | 2020 | 11 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1035 | 0.040 |
Why?
| | Models, Organizational | 1 | 2019 | 143 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 508 | 0.040 |
Why?
| | Long-Term Care | 1 | 2019 | 110 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 190 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 175 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1322 | 0.030 |
Why?
| | Skin | 1 | 2020 | 760 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2015 | 43 | 0.030 |
Why?
| | Rupture | 1 | 2015 | 88 | 0.030 |
Why?
| | Foot | 1 | 2015 | 99 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 612 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1671 | 0.030 |
Why?
| | Mental Health Services | 1 | 2018 | 445 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 845 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2792 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4073 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1970 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1234 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3512 | 0.020 |
Why?
| | Infant | 1 | 2022 | 9796 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 10475 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|